Benjamin Siemsen

Benjamin Siemsen, Ph.D., is an Associate Director of Preclinical Pharmacology at Supernus Pharmaceuticals, Inc., since August 2022, following a role as a Faculty Research Associate at the University of Maryland School of Medicine from July 2021 to August 2022. With a Ph.D. in Neuroscience from the Medical University of South Carolina, obtained in 2018, Benjamin Siemsen has extensive experience in preclinical research, particularly in psychiatric disorders, viral vector molecular engineering, and behavioral pharmacology. Previous positions include Postdoctoral Researcher and Graduate Research Assistant at the Medical University of South Carolina, where Benjamin Siemsen led several innovative research initiatives and collaborations while also contributing to grant writing, manuscript submissions, and training for graduate and postdoctoral trainees. Early experience includes roles as an Undergraduate Research Assistant at both the University of Nebraska-Lincoln and the University of Nebraska Medical Center, focusing on neuroinflammation and its effects on substance abuse and cognitive function.